Dupilumab subgroup responder analysis: a post hoc analysis from LIBERTY PRIME and PRIME2 in prurigo nodularis.
Brian S Kim, Shawn G Kwatra, Gil Yosipovitch et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc subgroup analysis pooled data from the randomized PRIME and PRIME2 trials, which enrolled 311 adults with prurigo nodularis and compared dupilumab 300 mg every 2 weeks with matching placebo for 24 weeks. The analysis assessed itch improvement, lesion improvement, and their combination across subgroups defined by age, gender, BMI, comorbidities, and prior treatment. At Week 24, dupilumab improved itch and lesions compared with placebo in every subgroup studied; statistical superiority was demonstrated in most subgroups.
Key findings
- At Week 24, dupilumab improved itch and lesions compared with placebo across all subgroups studied.
- Statistical superiority over placebo was demonstrated in most subgroups tested.
- Subgroups were stratified by age, gender, BMI, comorbidities, and prior medication use.
Why it matters
Prurigo nodularis can be difficult to manage, particularly when comorbidities or previous treatment failures complicate care. These findings suggest that the observed benefits of dupilumab were not confined to a particular demographic or clinical subgroup, supporting consideration of the breadth of the trial results when assessing treatment evidence. The analysis does not establish equal benefit in every subgroup.
What to keep in mind
This was a post hoc subgroup analysis of pooled trial data; statistical superiority was not demonstrated in every subgroup.